BioStock: Idogen’s study approved in Norway and Sweden

Idogen has received the go-ahead from both the Swedish and Norwegian Medical Products Agencies to initiate a clinical phase I/IIa study with the cell therapy IDO 8 in hemophilia A. The study’s primary purpose is to show that the treatment is safe and to obtain preliminary data on the potential treatment effect.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/04/idogens-study-approved-in-norway-and-sweden/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se